mAb-52 Antibody Composition for SARS-CoV-2 Variant Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing SARS-CoV-2 vaccines are susceptible to evolving escape variants, necessitating the development of vaccine compositions that target highly conserved regions of the virus to prevent mutation and reduce transmission and symptoms.
Innovation Solution
A composition comprising the mAb-52 monoclonal antibody, which targets the receptor binding domain of the SARS-CoV-2 spike protein, competes with ACE2, and is effective against a range of variants including WA1, BA.1, XBB.1.5, EG.5.1, BA.2.86, HV.1, and KP.2, administered at doses ranging from 5 mg/kg to 15 mg/kg.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing SARS-CoV-2 vaccines are used, then initial protection is provided, but escape variants can evolve that are less susceptible to the vaccine compositions
Solution Approach 1:
The vaccine composition is divided into multiple components: an mRNA vaccine component and a monoclonal antibody component (mAb-52). This segmentation allows each component to target different aspects of viral protection, with the mRNA inducing broad immune responses and the monoclonal antibody providing targeted neutralization against conserved epitopes, thereby maintaining effectiveness against escape variants.
Solution Approach 2:
The invention uses a composite vaccine composition combining mRNA technology with monoclonal antibody therapy. This composite approach integrates the advantages of both technologies: mRNA induces robust neutralizing antibody responses against multiple variants, while the monoclonal antibody mAb-52 provides immediate protection by binding to highly conserved RBD epitopes that are less prone to mutation, creating a synergistic effect that overcomes variant escape.
2Productivity
If vaccines target variable regions of the virus, then initial immune response is generated, but the virus can mutate to become less susceptible
Solution Approach 1:
The monoclonal antibody mAb-52 is engineered to recognize specific conserved epitopes within the RBD of the spike protein, particularly targeting class I/II RBD epitopes that are highly conserved across variants. This parameter change in target selection—from variable to conserved regions—ensures the antibody maintains binding affinity and neutralization capacity against diverse variants including WA1, BA.1, XBB.1.5, EG.5.1, BA.2.86, HV.1, and KP.2.
3Reliability
If monoclonal antibodies target highly conserved regions, then resistance to mutation is improved, but the complexity of identifying and developing such antibodies increases
Solution Approach 1:
The invention uses the RBD of the spike protein as an intermediary target that mediates between the antibody and the virus. By focusing on the RBD region, particularly conserved class I/II epitopes, the monoclonal antibody mAb-52 achieves reliable binding across variants. The RBD serves as a stable intermediate structure that can be targeted to achieve broad neutralization without requiring complex antibody engineering, as the conserved nature of the RBD simplifies the development process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mAb-52 antibody demonstrates potent neutralization capacity against multiple SARS-CoV-2 variants, reducing viral load and protecting against respiratory infections, including severe symptoms, by inducing robust mucosal immunity and neutralizing antibodies.
Implementation Method 1
the mAb-52 binds the RBD of the SARS-CoV-2 spike protein with interactions comprising polar and hydrophobic interactions of CDRH1, CDRH2, CDRH3, CDRL1, and CDRL3
Implementation Method 2
the mAb-52 binds the RBD of the SARS-CoV-2 spike protein with interactions comprising polar and hydrophobic interactions of CDRH1, CDRH2, CDRH3, CDRL1, and CDRL3
Implementation Method 3
the mAb-52 targets a receptor binding domain (RBD) of the SARS-CoV-2 spike protein and competes with ACE2
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of compositions and methods of use of mAb that prevent, inhibit, or reduce the transmissivity of SARS-CoV-2 infections.